Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Once dismissed and underdiagnosed, postural orthostatic tachycardia syndrome (POTS) has surged since the pandemic — with cases jumping 130% — and is finally getting the scientific attention it deserves. Emerging research points to an autoimmune root cause, and treatments are evolving beyond symptom management. Young women are disproportionately affected, and many long-COVID patients may actually have POTS.
POTS — a disorder of the autonomic nervous system causing dizziness, rapid heart rate, brain fog, and fatigue upon standing — was largely overlooked for decades. Then COVID hit. A study of over 65 million patient records found a 130% spike in POTS diagnoses post-pandemic, jumping from ~430 cases/month before March 2020 to ~990/month afterward. Young women are disproportionately affected, and viruses (now especially COVID) are the most common trigger.
The overlap with long COVID is striking: one study found 62.5% of long-COVID patients met formal POTS diagnostic criteria. Researchers now believe much of what's labeled "long COVID" may actually be the same postviral autonomic dysfunction seen for years — just sparked by a new virus.
Key Takeaways:
Why it matters: After decades of dismissal — particularly for women — POTS is finally attracting serious research funding and scientific scrutiny. If the autoimmune hypothesis holds up, existing rheumatologic drugs could offer a path to treating the root cause rather than just managing symptoms.
